Corvus Pharmaceuticals, Inc.
- Stock
- Ticker CRVS
- ISIN US2210151005
- Nasdaq
Performance, volatility and drawdowns of Corvus Pharmaceuticals, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $6,512. Global equities (VT): $29,042.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −97.0% in 03/2023, measured from the peak in 03/2017. It took 106 months to get back to the old peak.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | -8.1 | -9.9 | -10 | -11 | -12 | -15 | -19 | -21 |
| EBITDA | -8.1 | -9.9 | -10 | -11 | -12 | -15 | -19 | -21 |
| Net income | -12 | 15 | -8.0 | -10 | -12 | -14 | -18 | -20 |
| Earnings per share | -0.16 | -0.13 | -0.10 | -0.12 | -0.15 | -0.15 | -0.19 | -0.22 |
| Balance sheet | ||||||||
| Total assets | 69 | 59 | 89 | 80 | 71 | 253 | 239 | 224 |
| Liabilities | 36 | 10 | 9.2 | 8.7 | 9.9 | 13 | 14 | 16 |
| Equity | 33 | 49 | 80 | 72 | 61 | 241 | 225 | 208 |
| Cash | 8.7 | 5.0 | 15 | 2.9 | 4.6 | 40 | 19 | 15 |
| Cash flow | ||||||||
| Operating cash flow | -8.5 | -8.3 | -5.8 | -9.6 | -9.2 | -10 | -15 | -12 |
| Capital expenditure | – | 0.0 | -0.1 | 0.0 | 0.0 | -0.1 | -0.6 | -0.1 |
| Free cash flow | -8.5 | -8.3 | -5.9 | -9.6 | -9.2 | -10 | -16 | -12 |
Value it:DCF calculatorMultiples calculator
Annual returns
Best year 2024 at +204.0%, weakest 2022 at −64.7%. 4 of 9 full years were positive. * partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 5 Nov 2026 | −$0.22 |
| 6 Aug 2026 | −$0.19 |
| 7 May 2026 | −$0.15 |
| 12 Mar 2026 | −$0.15 |
| 4 Nov 2025 | −$0.12 |
| 7 Aug 2025 | −$0.10 |
| 8 May 2025 | −$0.13 |
| 25 Mar 2025 | −$0.16 |
| 12 Nov 2024 | −$0.60 |
| 6 Aug 2024 | −$0.07 |
| 7 May 2024 | −$0.12 |
| 19 Mar 2024 | −$0.13 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €739m
- Market cap in trading currency
- $816m
- Enterprise value
- $613m
- P/E
- –
- P/S
- –
- P/B
- 3.92
- EV/Sales
- –
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -5.9%
Results (last four quarters)
- Revenue
- –
- Gross profit
- –
- EBITDA
- −$67.6m
- Net income
- −$64.3m
- Earnings per share
- −$0.71
- Revenue per share
- –
- Revenue growth
- –
- Earnings growth
- –
Profitability
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity
- -45.9%
- Return on assets
- -28.7%
Balance sheet and cash flow
- Cash
- $203m
- Cash per share
- $2.41
- Financial debt
- –
- Debt/equity %
- –
- Current ratio
- 13.38
- Book value per share
- $2.47
- Operating cash flow
- −$47.2m
- Free cash flow
- −$47.9m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 84.4m
- Volume
- 927,500
- Avg. volume 3 months
- 1.04m
- Relative volume
- 0.9
Price and technicals
- Price
- $9.67
- 1 day
- −3.4%
- 52-week high
- $25.52
- 52-week low
- $6.50
- Distance to 52-week high
- −62.1%
- Distance to 52-week low
- +48.8%
- Distance to 50-day line
- −10.8%
- Distance to 200-day line
- −29.6%
- RSI (14)
- 40
- Volatility 1M
- 66.9%
Performance
- 1 week
- −9.1%
- 1 month
- −9.2%
- 3 months
- −31.4%
- 6 months
- −23.3%
- YTD
- +25.6%
- 1 year
- +8.7%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has CRVS performed since 11/2016?
$10,000 grew to $6,512 by 20 Nov 2026, which is −4.2% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is CRVS?
Volatility was 116.7% per year, measured on monthly returns. The largest decline from a peak was −97.0%, with the low in 03/2023.
How does CRVS compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, CRVS returned −4.2% at 116.7%. The correlation of monthly returns was 0.18; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.